指南与共识认知障碍与痴呆帕金森病与运动障碍

路易体痴呆的诊断与管理:DLB联盟第四次共识报告

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.
指南 / 共识 · Neurology · 2017-06-07

DLB联盟更新了路易体痴呆(DLB)的临床和病理诊断建议,修订版共识标准明确区分临床特征与诊断生物标志物,并增加REM睡眠行为障碍和123碘-间碘苄胍(MIBG)心肌闪烁显像的诊断权重。病理方法和标准有细微修改以考虑阿尔茨海默病神经病理变化。临床管理建议主要基于专家意见,因DLB随机对照试验较少。

要点

  • 修订版DLB共识标准区分临床特征与诊断生物标志物。
  • 增加REM睡眠行为障碍和MIBG心肌闪烁显像的诊断权重。
  • 临床管理建议主要基于专家意见,随机对照试验较少。

核心结论

  • 修订版DLB共识标准明确区分临床特征与诊断生物标志物,并增加REM睡眠行为障碍和MIBG心肌闪烁显像的诊断权重。
  • DLB已被纳入DSM-5作为伴路易体的major神经认知障碍。
  • 临床管理建议主要基于专家意见,因DLB随机对照试验较少。

研究设计与样本

  • DLB联盟对既往共识报告进行更新,修订临床和病理诊断建议。

主要发现

  • 修订版共识标准区分临床特征与诊断生物标志物,并给出建立和解释这些指标的最佳方法指导。
  • 增加了关于REM睡眠行为障碍和123碘-MIBG心肌闪烁显像的诊断权重的新信息。
  • 描述了其他神经影像、电生理和实验室检查的诊断作用。
  • 建议对病理方法和标准进行细微修改,以考虑阿尔茨海默病神经病理变化、增加先前遗漏的路易体相关病理类别,并包括黑质神经元丢失评估。

关键数值与推荐

  • 修订版DLB共识标准明确区分临床特征与诊断生物标志物。
  • 增加REM睡眠行为障碍和123碘-MIBG心肌闪烁显像的诊断权重。
  • 病理标准修改包括考虑阿尔茨海默病神经病理变化、增加路易体相关病理类别和黑质神经元丢失评估。

临床怎么用

  • 临床诊断DLB时应区分临床特征与诊断生物标志物,并重视REM睡眠行为障碍和MIBG心肌闪烁显像。
  • 病理诊断需考虑阿尔茨海默病神经病理变化、路易体相关病理类别和黑质神经元丢失。
  • 临床管理建议主要基于专家意见,需结合个体情况应用。

局限性

  • 临床管理建议主要基于专家意见,因DLB随机对照试验较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017. PMID: 28592453. doi:10.1212/WNL.0000000000004058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。